Avibactam Sodium

CHEMBL2107817 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

287.2 g/mol

LogP

—

Phase

4

The sodium salt of avibactam, formulated for intravenous use in combination with ceftazidime to treat serious infections caused by drug-resistant Gram-negative bacteria. By protecting the partner antibiotic from enzymatic destruction, it restores its bactericidal activity.

Molekularmasse

287,2300 g/mol

TPSA

141,00 Å²

Therapeutische Bereiche

Infectious Disease

Wirkmechanismus

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)[O-].[Na+]

InChI

InChI=1S/C7H11N3O6S.Na/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);/q;+1/p-1/t4-,5+;/m1./s1

Molecular Formula

C7H10N3NaO6S

HBD / HBA

1 / 6

Rotierbare Bindungen

3

Schwere Atome

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The sodium salt of avibactam, formulated for intravenous use in combination with ceftazidime to treat serious infections caused by drug-resistant Gram-negative bacteria. By protecting the partner antibiotic from enzymatic destruction, it restores its bactericidal activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Avibactam Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107817. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 24944097. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Avibactam Sodium auf PillFYI

Struktur

Schnelldaten

Formel: C7H10N3NaO6S

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.